Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $4.31 billion. The enterprise value is $4.39 billion.
Important Dates
The last earnings date was Tuesday, November 5, 2024, after market close.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RARE has 92.28 million shares outstanding. The number of shares has increased by 22.79% in one year.
| Current Share Class | 92.28M |
| Shares Outstanding | 92.28M |
| Shares Change (YoY) | +22.79% |
| Shares Change (QoQ) | +10.30% |
| Owned by Insiders (%) | 3.49% |
| Owned by Institutions (%) | 97.21% |
| Float | 89.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.71 |
| Forward PS | 7.35 |
| PB Ratio | 12.34 |
| P/TBV Ratio | 31.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.81, with a Debt / Equity ratio of 2.58.
| Current Ratio | 2.81 |
| Quick Ratio | 2.47 |
| Debt / Equity | 2.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.26 |
Financial Efficiency
Return on equity (ROE) is -289.98% and return on invested capital (ROIC) is -29.76%.
| Return on Equity (ROE) | -289.98% |
| Return on Assets (ROA) | -24.12% |
| Return on Capital (ROIC) | -29.76% |
| Revenue Per Employee | $409,675 |
| Profits Per Employee | -$438,078 |
| Employee Count | 1,276 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 19.17 |
Taxes
| Income Tax | -2.09M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.09% in the last 52 weeks. The beta is 0.58, so RARE's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +16.09% |
| 50-Day Moving Average | 53.60 |
| 200-Day Moving Average | 48.11 |
| Relative Strength Index (RSI) | 35.61 |
| Average Volume (20 Days) | 974,450 |
Short Selling Information
The latest short interest is 3.18 million, so 3.45% of the outstanding shares have been sold short.
| Short Interest | 3.18M |
| Short Previous Month | 3.16M |
| Short % of Shares Out | 3.45% |
| Short % of Float | 3.57% |
| Short Ratio (days to cover) | 5.09 |
Income Statement
In the last 12 months, RARE had revenue of $522.75 million and -$558.99 million in losses. Loss per share was -$6.43.
| Revenue | 522.75M |
| Gross Profit | -197.59M |
| Operating Income | -535.74M |
| Pretax Income | -586.86M |
| Net Income | -558.99M |
| EBITDA | -501.06M |
| EBIT | -535.74M |
| Loss Per Share | -$6.43 |
Full Income StatementBalance Sheet
The company has $607.51 million in cash and $912.50 million in debt, giving a net cash position of -$101.90 million or -$1.10 per share.
| Cash & Cash Equivalents | 607.51M |
| Total Debt | 912.50M |
| Net Cash | -101.90M |
| Net Cash Per Share | -$1.10 |
| Equity (Book Value) | 353.83M |
| Book Value Per Share | 3.76 |
| Working Capital | 514.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$418.59 million and capital expenditures -$8.44 million, giving a free cash flow of -$427.03 million.
| Operating Cash Flow | -418.59M |
| Capital Expenditures | -8.44M |
| Free Cash Flow | -427.03M |
| FCF Per Share | -$4.63 |
Full Cash Flow StatementMargins
Gross margin is -37.80%, with operating and profit margins of -102.49% and -106.93%.
| Gross Margin | -37.80% |
| Operating Margin | -102.49% |
| Pretax Margin | -107.33% |
| Profit Margin | -106.93% |
| EBITDA Margin | -95.85% |
| EBIT Margin | -102.49% |
| FCF Margin | -99.73% |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.79% |
| Shareholder Yield | -22.79% |
| Earnings Yield | -12.95% |
| FCF Yield | -9.89% |
Dividend DetailsAnalyst Forecast
The average price target for RARE is $86.79, which is 85.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $86.79 |
| Price Target Difference | 85.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 37.91% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -1.96 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.96 |
| Piotroski F-Score | 4 |